Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen

Publication
Article
OncologyONCOLOGY Vol 23 No 4
Volume 23
Issue 4

A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.

A phase III clinical trial of sunitinib (Sutent) has been stopped early after the drug showed significant benefit in patients with advanced pancreatic neuroendocrine tumors. An independent data monitoring committee recommended halting the trial after concluding that sunitinib demonstrated greater progression-free survival compared with placebo plus best supportive care in these patients.

All patients in the trial will have the option to continue taking sunitinib or be switched from placebo to sunitinib. The full data set from this trial is being analyzed and more details will be presented at an upcoming scientific meeting.

Articles in this issue
Despite Past Disappointments the Future of Melanoma Therapy Appears Bright
Everolimus Approved for Advanced Kidney Cancer
Report Shows Record Number of Cancer Drugs in Development
Sunitinib Study in Pancreatic Cancer Stopped Early After Significant Benefit Seen
Black Cohosh (Cimicifuga racemosa)
Black Cohosh (Cimicifuga racemosa)
Clinical Trials and Radiation Oncology Technologies
Evaluating Advanced Technologies in Radiation Oncology: When and How Should Randomized Trials Be Done?
Current Status and Future Potential of Advanced Technologies in Radiation OncologyPart 2. State of the Science by Anatomic Site
Health Literacy: Improving Patient Understanding
Health Literacy, Communication, and Treatment Decision-Making in Older Cancer Patients
The Role of Adjuvant Radiation in Endometrial Cancer
The Role of Adjuvant Radiation in Endometrial Cancer
Resolving the Confusion Surrounding Adjuvant Radiation in Endometrial Cancer
Studies of Adjuvant Treatment for Endometrial Cancer
Landmark Study Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer
Maintenance Rituximab Useful in Advanced Indolent Lymphoma
Related Videos
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
Related Content
69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

April 21st 2024
Article
Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Diane M. Simeone, MD “Thrilled” To Be UCSD Moores Cancer Center Director

February 26th 2024
Podcast

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

April 19th 2024
Article

Omid Hamid, MD, gives his perspective on the use of tumor-infiltrating lymphocyte therapy for patients with melanoma.

Oncology Peer Review On-The-Go: Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

Oncology Peer Review On-The-Go: Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

May 7th 2022
Podcast

Christine Chung, DO, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® about implications of blood-based molecular markers in pancreatic adenocarcinoma.

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

miRNA Assay May Lead to Early Detection in PDAC

April 8th 2024
Article

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

The Impact of CAR T-Cell Therapy on Hematological Malignancies

The Impact of CAR T-Cell Therapy on Hematological Malignancies

March 11th 2024
Article

Jae Park, MD, discussed the use of CAR T-cell therapy across the hematologic malignancies space.